{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:35:49Z","timestamp":1794274549316,"version":"4.9.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Limited evidence exists for healthcare resource utilization (HCRU) and costs associated with generalized myasthenia gravis (gMG), a rare autoimmune disorder, for adults in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with \u22651 diagnostic claim for MG between 2014 and 2019 were identified using Symphony Health's Integrated Dataverse\u00ae. Using a novel algorithm, HCRU and costs over 12 months following index dates were evaluated for patients with gMG including those with exacerbation events. For patients who experienced crisis events, HCRU and costs were analyzed during the 36 months preceding, during, and 12 months following the events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02). For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99). Cost increases were, in large part, attributed to treatments received.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>New diagnosis, exacerbation, and crisis events were drivers of HCRU and cost for patients with gMG. Particularly, high costs of gMG-specific medications associated with intervention for exacerbation and crisis events contributed to increased all-cause costs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2021.809999","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:26:34Z","timestamp":1642515994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States"],"prefix":"10.3389","volume":"12","author":[{"given":"Glenn","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Whangbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankha","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Investig."},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B4","unstructured":"2015"},{"key":"B5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve."},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","article-title":"Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database","volume":"10","author":"Murai","year":"2019","journal-title":"Clin Exp Neuroimmunol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1212\/WNL.92.15_supplement.P5.4-037","article-title":"Burden of disease in patients with refractory myasthenia gravis (P5.4-037).","volume":"92","author":"Sharma","year":"2019","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large US insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B12","first-page":"1","article-title":"Hypertension prevalence and control among adults: United States, 2015-2016","author":"Fryar","year":"2017","journal-title":"NCHS Data Brief."},{"key":"B13","unstructured":"2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"63","author":"El-Serag","year":"2014","journal-title":"Gut."},{"key":"B15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.15585\/mmwr.mm6922a5","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1089\/thy.2006.0235","article-title":"Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002)","volume":"17","author":"Aoki","year":"2007","journal-title":"Thyroid."},{"key":"B17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Sanders DB. Estimated cost of treating myasthenia gravis in an insured US population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve."},{"key":"B18","unstructured":"Trends in outcomes and hospitalization charges among mechanically ventilated patients with myasthenia gravis in the United States20914 SouayahN NasarA SuriMF KirmaniJF EzzeddineMA QureshiAI 23675139Int J Biomed Sci.52009"},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijcard.2019.09.054","article-title":"Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association","volume":"299","author":"Desai","year":"2020","journal-title":"Int J Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study","volume":"13","author":"Heatwole","year":"2011","journal-title":"J Clin Neuromuscul Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaad.2019.07.029","article-title":"Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients","volume":"82","author":"Narla","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mus.25624","article-title":"Inpatient cost analysis for treatment of myasthenia gravis","volume":"56","author":"Omorodion","year":"2017","journal-title":"Muscle Nerve."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107494","DOI":"10.1016\/j.yebeh.2020.107494","article-title":"Economic burden associated with tuberous sclerosis complex in patients with epilepsy","volume":"112","author":"Betts","year":"2020","journal-title":"Epilepsy Behav."},{"key":"B25","first-page":"42","article-title":"Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States","volume":"10","author":"Lee","year":"2017","journal-title":"Am Health Drug Benefits."},{"key":"B26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/COPD.S238408","article-title":"Patient characteristics and healthcare resource utilization among patients with COPD new to LAMA\/LABA fixed-dose combination treatment in US-based real-world practice","volume":"15","author":"Ding","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","article-title":"Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis","volume":"60","author":"Harris","year":"2019","journal-title":"Muscle Nerve."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.809999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:47:55Z","timestamp":1726498075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.809999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":30,"alternative-id":["10.3389\/fneur.2021.809999"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.809999","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fneur.2021.809999.s001","asserted-by":"subject"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"809999"}}